High throughput pharmacological screening for anti-coronaviral compounds
The global SARS-CoV-2 pandemic is responsible for hundreds of thousands of deaths globally. Anti-viral therapeutic strategies are desperately needed to attenuate SARS-CoV-2-associated disease. We have initiated a high-throughput pharmacologic screen of a unique metabolism-focused compound library to identify drugs that limit coronavirus infection in pulmonary human fibroblasts. Our preliminary data has identified several compounds that substantially inhibit coronavirus infection. Our laboratory is in the process of validating the anti-viral activity of these compounds against SARS-CoV-2. In addition, we are elucidating how coronaviruses modulate cellular metabolism to support productive infection in an attempt to identify viral metabolic vulnerabilities that might be targeted for further therapeutic development.
« back to all projects